|
Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial. |
|
|
Stock and Other Ownership Interests - Merck |
Honoraria - Bayer; Genentech; GlaxoSmithKline; IGM Biosciences; Immunovaccine; Janssen; Pharmacyclics; Roche; Seagen; Takeda |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Genentech; Juno Therapeutics; Merck; Roche; Rocket Medical; Seagen; Takeda; Teva |
Research Funding - Bayer; Genentech; GlaxoSmithKline; IGM Biosciences; IGM Biosciences; Immunovaccine; Janssen; Pharmacyclics; Roche; Rocket Medical; Seagen |
Travel, Accommodations, Expenses - Bayer; Genentech; Roche; Seagen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kyowa Kirin; MSD; Portola Pharmaceuticals; Roche; Sandoz; Sanofi; SERVIER; Takeda; TG Therapeutics; Verastem |
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kyowa Kirin; MSD; Portola Pharmaceuticals; Roche; Sandoz; SERVIER; Verastem |